US 12,216,119 B2
IGF-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions
Jian Guan, Auckland (NZ)
Assigned to THE CGP LAB LIMITED, (NZ)
Appl. No. 16/642,863
Filed by THE CGP LAB LIMITED, Rangiora (NZ)
PCT Filed Aug. 28, 2018, PCT No. PCT/NZ2018/050116
§ 371(c)(1), (2) Date Feb. 27, 2020,
PCT Pub. No. WO2019/045575, PCT Pub. Date Mar. 7, 2019.
Claims priority of application No. 735002 (NZ), filed on Aug. 28, 2017; and application No. 742311 (NZ), filed on May 7, 2018.
Prior Publication US 2021/0072240 A1, Mar. 11, 2021
Int. Cl. G01N 33/569 (2006.01); A61K 31/352 (2006.01); A61K 31/7048 (2006.01); A61K 36/185 (2006.01)
CPC G01N 33/56966 (2013.01) [A61K 31/352 (2013.01); A61K 31/7048 (2013.01); A61K 36/185 (2013.01); G01N 2410/00 (2013.01); G01N 2800/28 (2013.01)] 3 Claims
 
1. A method of treating a stroke or Parkinson's disease in a human in need thereof consisting essentially of:
a) obtaining a biological specimen from the human in need thereof;
b) measuring the concentration of cyclic glycine-proline (cGP) and/or a ratio of cGP concentration to the total measured amount of IGF-1 in the biological specimen from the human in need thereof, as a biomarker for an active, concentration-dependent IGF-1 bioavailability in the biological specimen from the human;
c) comparing either the measured cGP concentration and/or the ratio of cGP concentration to the total measured amount of IGF-1 in the biological specimen from the human to a standard, wherein the standard is based on data collected for a cGP concentration and/or a ratio of cGP concentration to total measured amount of IGF-1 in:
(i) the stroke or Parkinson's disease human; and/or
(ii) a human population of stroke or Parkinson's disease human patients to confirm whether or not the human has an altered cGP concentration and/or ratio of cGP concentration to the total measured amount of IGF-1 compared to the standard;
d) selecting the human for treatment based on the measured cGP concentration or ratio of cGP concentration to total measured amount of IGF-1 compared to the standard; and
e) administering a therapeutically effective amount of a blackcurrant extract to the selected human for treatment, wherein the therapeutically effective amount of the blackcurrant extract is a dose of 50 mg to 1000 mg of the blackcurrant extract to the selected human per day to effectively treat the stroke or the Parkinson's disease in the selected human.